Related references
Note: Only part of the references are listed.B-Raf and the inhibitors: from bench to bedside
Tiangui Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Muhammad Khattak et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2013)
Targeting Metastatic Melanoma
Keith T. Flaherty
ANNUAL REVIEW OF MEDICINE, VOL 63 (2012)
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
Irene Brana et al.
BMC MEDICINE (2012)
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2012)
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Yingjun Su et al.
CLINICAL CANCER RESEARCH (2012)
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2012)
Melanoma: from mutations to medicine
Hensin Tsao et al.
GENES & DEVELOPMENT (2012)
Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
Richard W. Joseph et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Specifically targeting ERK1 or ERK2 kills Melanoma cells
Jianzhong Qin et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
Sara A. Byron et al.
MOLECULAR CANCER (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Georgia Hatzivassiliou et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Sergey I. Nikolaev et al.
NATURE GENETICS (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas
Murielle Mimeault et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2012)
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Inna V. Fedorenko et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A
Imanol Arozarena et al.
CANCER CELL (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
Chen Chen Jiang et al.
CLINICAL CANCER RESEARCH (2011)
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst et al.
CLINICAL CANCER RESEARCH (2011)
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
Poulam M. Patel et al.
EUROPEAN JOURNAL OF CANCER (2011)
New drugs in melanoma: It's a whole new world
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Use of DNA Microarray and Small Animal Positron Emission Tomography in Preclinical Drug Evaluation of RAF265, a Novel B-Raf/VEGFR-2 lInhibitor
Jeffrey R. Tseng et al.
NEOPLASIA (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer
Jer-Yen Yang et al.
CANCER RESEARCH (2010)
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Hong Yang et al.
CANCER RESEARCH (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells
Yongping Shao et al.
CANCER RESEARCH (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: A new potential therapy for the treatment of melanoma
Thomas B. Karasic et al.
EXPERIMENTAL CELL RESEARCH (2010)
Molecular therapeutic approaches to melanoma
Zhenyu Ji et al.
MOLECULAR ASPECTS OF MEDICINE (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice
Matthew W. VanBrocklin et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
John T. Lee et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Steven Whittaker et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
William D. Tap et al.
NEOPLASIA (2010)
Small molecules and targeted therapies in distant metastatic disease
P. Hersey et al.
ANNALS OF ONCOLOGY (2009)
Tumour cell survival signalling by the ERK1/2 pathway
K. Balmanno et al.
CELL DEATH AND DIFFERENTIATION (2009)
Melanoma Epidemiology and Public Health
Marianne Berwick et al.
DERMATOLOGIC CLINICS (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. M. Smalley et al.
ONCOGENE (2009)
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2008)
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
MP Hoeflich et al.
CANCER RESEARCH (2006)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy
VSK Yee et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
B-raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts
CA Pritchard et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
